Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

Share Price is delayed by 15 minutes
Get Live Data
2.50    0.00 (0.00%)
Bid:
2.50
Ask:
2.80
Spread: 0.30 (12.00%)
Market Cap: £4.56m
NANO Live PriceLast checked at - London Stock Exchange

Intraday Nanoco Share Chart

New Commercialisation Strategy in Display

31 Mar 2016 07:00

RNS Number : 6262T
Nanoco Group PLC
31 March 2016
 

For immediate release

31 March 2016

 

 

 

NANOCO GROUP PLC

("Nanoco" or the "Company")

 

Adopts New Commercialisation Strategy in Display

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, announces that it has mutually agreed with The Dow Chemical Company (NYSE: DOW) ("Dow") to modify its licence agreement for Nanoco's cadmium-free quantum dot technology. Under the modified agreement, Dow has non-exclusive rights for the sale, marketing and manufacture of Nanoco's quantum dot technology for use in display applications while Nanoco is free to pursue a range of routes to market.

This new display strategy will allow Nanoco to maximise the roll-out of its technology and give the Company greater control over the commercialisation of its intellectual property in the display industry. In the near term the Company intends to develop new partnerships to serve the display sector as well as to manufacture, market and sell its cadmium-free quantum dot products directly from the Company's own plant in Runcorn.

 

Amid a very positive market backdrop it is an exciting time for the Company to gain further control of its strategy in the display industry. Cadmium-free quantum dots are expected to be at the centre of a major, emerging industry in consumer electronics, with DisplaySearch forecasting that 18.7 million quantum dot TVs will be shipped in 2018.

 

As a result of changing the Dow agreement to non-exclusive, Nanoco will receive a lower royalty rate from Dow on Dow's sales of cadmium-free quantum dot products and the Company will not receive earn-out income from Dow. Nanoco-generated sales of cadmium-free quantum dots will be satisfied by production from the Company's own plant in Runcorn. All other terms of the agreement with Dow remain unchanged. It is anticipated that Nanoco's revenues in the current financial year will be lower than previously expected as a result of this new agreement. However, the Company anticipates that it will lead to higher revenues in future years.

 

The change in the licensing agreement does not affect commercial production of Dow's TREVISTA™ cadmium-free quantum dots at Dow's large scale quantum dot facility in Cheonan, South Korea, which is now supplying sample material to meet potential customers' requirements in line with the timetable indicated in Nanoco's AGM statement issued in December 2015.

 

"Nanoco's cadmium-free quantum dot technology continues to fit well with what our customers want and with our desire to develop products and services that are more sustainable for the future," said Andrew Lee, Global Business Director, Dow Display Technologies. "We are pleased that we can bring consistent, reliable, high-volume supply of our TREVISTA™ quantum dots based on Nanoco's cadmium-free technology to the market."

 

Michael Edelman, Nanoco's CEO, commented: "We now have a multifaceted strategy in display in which we have a non-exclusive licence agreement with Dow along with the opportunity to form new partnerships and to work independently. We believe this is a very significant development for Nanoco as we are gaining greater control over the commercialisation of our technology in display against a very positive market backdrop."

 

Nanoco intends to release its interim results for the six months ended 31 January 2016 on 12 April 2016.

 

 

 

For further information, please contact:

 

Nanoco

Tel: +44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

David Blain, Chief Financial Officer

Caroline Watson, Investor Relations Manager

cwatson@nanocotechnologies.com

Tel: + 44 (0) 7799 897357

Canaccord Genuity - Joint Broker

Tel: +44 (0) 20 7523 8000

Simon Bridges

Cameron DuncanMark Whitmore

Liberum - Joint Broker

Tel: +44 (0) 20 3100 2000

Neil Patel

Richard Bootle

Steven Tredget

Buchanan

Tel: +44 (0) 20 7466 5000

Mark Court / Sophie Cowles / Stephanie Watson

 

 

Notes for editors:

 

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nano-materials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, it has a licensing agreement with The Dow Chemical Company.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

 

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMGFFMGGGVZZ
Date   Source Headline
1st Jul 202610:24 amRNSPDMR Shareholding and Deferred Bonus Options
26th Jun 20267:00 amRNSCommencement of Shareholder Consultation
25th Jun 20267:00 amRNSBoard Update
19th Jun 202610:33 amRNSAdjournment of General Meeting
18th Jun 20267:00 amRNSIntention to adjourn General Meeting
9th Jun 20267:00 amRNSGlass Lewis recommendation
5th Jun 202611:55 amRNSTR-1: Notification of major holdings
27th May 20267:00 amRNSIntention to delist from London Stock Exchange
20th Apr 20265:37 pmRNSDirector/PDMR Shareholding
20th Apr 20267:00 amRNSInterim Results
13th Apr 20267:00 amRNSNotice of Results
26th Mar 20267:00 amRNSShoei Litigation Conclusion
19th Mar 20267:00 amRNSStay of Shoei Litigation
23rd Feb 20267:00 amRNSShoei Litigation Update
26th Jan 20267:00 amRNSConclusion of CDX process & Directorate changes
15th Jan 20261:08 pmRNSReceipt of Litigation Proceeds
13th Jan 20264:50 pmRNSResult of AGM
12th Jan 20267:00 amRNSLitigation update
9th Dec 20257:00 amRNSBlocklisting Six-Monthly Return
8th Dec 202511:16 amRNSNotice of AGM
27th Nov 20257:00 amRNSResponse to non-infringement claim
26th Nov 20257:00 amRNSAnnual Report and Accounts
20th Nov 20257:00 amRNSLitigation outcome – Settlement agreed
18th Nov 20257:07 amRNSPreliminary Results
13th Nov 20257:00 amRNSNotice of Results
4th Nov 20257:06 amRNSExtension of Joint Development Agreement
15th Oct 20257:00 amRNS-RAwarding of Government Grant
30th Sep 20254:30 pmRNSTotal Voting Rights and Share Capital
8th Sep 20257:00 amRNSIssue of Equity and Director/PDMR Shareholdings
19th Aug 20257:00 amRNSFull Year Trading Update & Director Retirement
9th Jun 20257:00 amRNSBLOCKLISTING SIX-MONTHLY RETURN
28th Apr 202510:48 amRNSJoint Development Agreement
25th Apr 20257:00 amRNSPatent infringement lawsuit against LG
17th Apr 20253:54 pmRNSHigh Court Confirmation of Capital Reduction
15th Apr 20257:00 amRNSInterim Results & Investor Presentation
13th Mar 20257:00 amRNSNotice of Results
21st Jan 20252:20 pmRNSAnnual General Meeting – Voting Results
18th Dec 20248:26 amRNSDirector/PDMR Shareholding
13th Dec 20241:23 pmRNSResult of General Meeting
9th Dec 20247:00 amRNSBlock Listing Six Monthly Return
6th Dec 20246:30 pmRNSNotice of AGM
29th Nov 20247:00 amRNSGlass Lewis and ISS recommendations
28th Nov 20243:23 pmRNSDirector/PDMR Shareholding
28th Nov 20241:25 pmRNSDirector/PDMR Shareholding
25th Nov 20247:00 amRNS2024 Annual Report
20th Nov 20247:00 amRNSPreliminary Results
15th Nov 202411:00 amRNSPosting of Circular and Notice of General Meeting
30th Oct 20247:01 amRNSCompletion of Buyback Programme
30th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
29th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.